Mitomycin Ophthalmic Solution Recalled for Sterility Assurance Concerns
The Compounding Pharmacy of America is recalling Mitomycin 0.03% Ophthalmic Solution due to FDA inspection findings of GMP violations that may impact sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of assurance of sterility in a medical product, which aligns with the rubric criteria for Severe severity (FDA Class II with potential for significant injury).
Plain-English summary
The Compounding Pharmacy of America is recalling Mitomycin 0.03% Ophthalmic Solution, single dose dropper, Keep Frozen. The recall is being conducted because an FDA inspection identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility.
The recall covers all lots distributed between November 2014 and May 2015. The specific lot codes and expiration dates are listed in the recall documentation. The product was distributed nationwide.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Mitomycin 0.03% Ophthalmic Solution, ml single dose dropper, Keep Frozen, The Compounding Pharmacy of America, Knoxville, TN
- Manufacturer
- The Compounding Pharmacy of America
- Category
- Drug — Ophthalmic Solution
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- All lots distributed between November 2014 and May 2015
- 05112015@22
- 5/10/2016
- 10202014@63
- 10/20/2015
- 10272014@17
- 10/27/2015
- 11102014@20
- 11/10/2015
- 12302014@8
- 12/30/2015
- 08252014@26
- 8/25/2015
- 08262014@20
- 8/26/2015
- 09052014@13
- 9/5/2015
- 01262015@15
- 1/26/2016
- 01022015@22
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 382 recalled by The Compounding Pharmacy of America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 382 products in this recall →Related recalls
Same manufacturer · The Compounding Pharmacy of America
See all →- CriticalFDA Recalls Non-Sterile HCG and Methylcobalamin Injection Vials
FDA (Drugs) · 2018-02-21
- SevereFDA Recalls Morphine and Ropivacaine Compounded Solution Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereHydromorphone Solution Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereMorphine and Bupivacaine Solution Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereMethylcobalamin Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMitomycin Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-06-12
- HighMitomycin Ophthalmic Solution Recalled Nationwide Over Sterility Assurance
FDA (Drugs) · 2023-02-01
- HighFDA Recalls Mitomycin Ophthalmic Solution for Sterility Assurance Failure
FDA (Drugs) · 2023-02-01
- SevereMedical Center Pharmacy Recalls Mitomycin Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2020-04-08
- SevereRXQ Compounding Recalls Mitomycin Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereMitomycin 0.04% Solution Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-07-10